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Background
HIV associated BL remains of concern for toxicity of
dose-intensive regimens used in HIV negative patients
(pts). Less intensive regimens have a high relapse rate.
We modified CODOX-M/IVAC hoping to preserve effi-
cacy while improving tolerability, particularly treatment
related mortality (TRM). Primary object: improving 1
year overall survival (OS) from the historical 65 to 85%.
Methods
Modifications of the US NCI regimen include rituximab
(R), cyclophosphamide reduction [800 mg/m2 x 2 days],
vincristine 2 mg cap, methotrexate (mtx) 3000 mg/m2,
dual chemotherapy lumbar punctures and IVAC infu-
sion (high risk pts). Antibiotic prophylaxis & growth fac-
tor support specified, 100% grade IV hematopoietic
toxicities in the original regimen. HAART therapy at the
discretion of the local MD. Pathology review included
CD20, CD10, BCL2, BCL6, p53, Ki67, BLIMP1, IRF4/
MUM1 and EBV EBER. (Table 1)
Results
Accrual of 33 planned pts by April 2010. Baseline: Classical
Burkitt, 97%; Low/High Risk, 9/91%; Median (range) Age
42 (19 – 55); CD4 count 195 (0 - 721), CD4 <100,
5 (27%);
HIV viral load 1819 (Undetectable – 1,187,968). Median
follow up (fu) is 9 mos for surviving pt. Number of pts with
gr3/4 toxicity: any 20 (61%), 13 (39%) hematologic,
16 (48%) infection including 7 febrile neutropenia, 6 meta-
bolic with 1 tumor lysis syndrome, 4 neurologic, 2 throm-
botic and 1 each coagulation, GI or pain. Only 2 gr 1/2
stomatitis/mucositis; 0 had gr 3/4. Six deaths: encephalopa-
thy with hepatic failure, hepatitis B and pneumonia (1), dis-
ease progression (3) including 1 in the CNS; fungal
infection (1); HIV. Median 1 year OS (n=34) was 81.7%
(61.0%, 92.1%) with a 35 mo median survival. OS by non-
BL defining proteins: EBER +/- (8/16) and p53 +/- (10/10)
were not predictive. IRF4/MUM1 +/- (8/15) highly predic-
tive in overall pts, but not in the confirmed Burkitt +/-
(6/14) with only 1 IRF4/MUM1 neg pt dying of BL.
Conclusions
AMC 048 with a median fu of 9 mos has a 1 yr OS of 82%
in BL. Relapses after 1 year are rare. TRM was zero. R did
not appear to increase toxicity. Only 5 pts withdrew due
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Table 1
Status N (%)
Treatment Completed per protocol 21 (62%)
Disease Progression 3 (9%)
Early termination due to adverse event* 5 (15%)
Early termination due to patient withdrawal** 2 (6%)
Early termination – counts did not recover within time frame
to begin cycle 4
1 (3%)
Treatment ongoing 2 (6%)
*1 pt with grade (gr) 4 thrombocytopenia and gr 3 infection; 1 pt with gr 3
left hemiparesis; 1 pt with gr 3 confusion unrelated to treatment; 1 pt with
prior hepatitis B and cirrohosis had gr 3 encephalopathy and pulmonary
infiltrates; 1 pt with gr 4 neutropenia and gr4 thrombocytopenia.
**1 CR 2 yrs post treatment.
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Results compare favorably with 2 studies of HIV neg pts.
Magrath (1995) reported 100% grade 4 hematologic and
20% grade 4 mucositis in 39 adults, 33 children (92% 2 yr
EFS). MRC/NCRI LY10 trial (Mead 2008) reduced mtx
(3gr/m2), but reported 9% TRM (64% 2 yr OS). IRF4/
MUM1 deserves further study in BL.
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